A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

Disclosed is a drug vaporization and inhalation device. The present invention is configured such that when an infected patient with asthma, a coronavirus, or the like inhales a particulate drug, the drug is contained in vaporized steam, and therefore, the drug can sufficiently arrive at the lungs of the infected patient with asthma, a coronavirus, or the like, without loss, thereby preventing a given amount of the drug from remaining in an inhalation container and improving the drug inhalation efficiency of the infected patient with asthma, a coronavirus, or the like along with prevention of excessive inhalation of the drug.

Implementations of a delivery device and method are disclosed. One implementation is a delivery device comprising a flow chamber with an inlet port for receiving a fluid flow in the flow chamber, and an outlet port for exiting a material from the flow chamber. The flow chamber may include a formation portion in which a suspension of the material is formed, and a collection portion that directs the suspension toward and/or into the outlet port. An amount of the material may collect in the collection portion adjacent the outlet port. The device may further comprise an insertion port for permitting insertion of the material in the flow chamber, and/or a pusher operable to move the amount of material through the outlet port. Related devices and methods also are disclosed.

A nebulizer assembly for a respiratory device is provided having a housing defining a chamber. The housing also has a nebulizer port configured to receive a nebulizer to discharge atomized medication into the chamber. An outlet of a handle is coupled to the inlet of the housing. A hose is coupled to an inlet of the handle. A patient interface is coupled to the outlet of the housing. Air flows from the hose to the patient interface via the handle and the housing. The air mixes with the atomized medication within the chamber.

A vaporization device is provided having a plurality of pens each having a battery, a mouthpiece, and a ventilated end. A vaporization device is also provided which is disposable having a plurality of pens, each having a vaporization chamber containing a coil, a battery, a PCB, a sensor, and a tank containing e-liquid for vaporization in the pen vaporization chamber through the coil of the pen to create a vaporization product which is mixed in a vapor port of the device through which a plurality of vaporization products are delivered to a user through the mouthpiece of the device in a single vaporization event.

Disclosed are methods and devices for processing lipoaspirate that include mechanically-processing harvested lipoaspirate in a liposuction filter canister. In some embodiments, the devices are liposuction devices that include a lipoaspirate processing unit for mechanically-processing lipoaspirate. The mechanical processing reduces the average size of adipose tissue pieces in the lipoaspirate without substantially rupturing lipocytes therein.

Disclosed is a barrier tent comprising a canopy, at least a portion of the canopy being composed of flexible sheet material; a frame for supporting the canopy; the canopy and frame being configured such that an internal surface of the canopy defines at least a portion of a patient segregation cavity to enclose a patient's head and at least a portion of the patient's body within the patient segregation cavity; and a gas input extending through the canopy, the gas input being positioned at a location configured such that supply of a gas through the input limits movement of aerosolised particles generated by or adjacent the patient toward the internal surface of the canopy.

The invention provides an apparatus for use in aerosolized delivery of a powder, and comprises a first chamber containing gas at a first pressure higher than atmospheric pressure, and a second chamber containing gas at a second pressure higher than atmospheric pressure. The apparatus also comprises a powder, contained within the first or second chamber. The first chamber has a first external wall and a separating wall, the separating wall being shared with the second chamber. The first external wall or the separating wall is configured to rupture if the pressure difference across it becomes equal to or greater than a threshold pressure difference. In particular, the apparatus is configured so that the difference between the second pressure and atmospheric pressure is greater than the threshold pressure difference. In an initial state, the apparatus is configured such that the difference between the second pressure and the first pressure is less than the pressure difference required to rupture the separating wall, and the difference between the first pressure and atmospheric pressure is less than the pressure difference required to rupture the first external wall.

A humidification system has a humidification source and a main gases flow path. The main gases flow path has a low pressure region and a high pressure region. In some embodiments, each of the low pressure region and the high pressure region has an aperture. The pressure difference between the apertures promotes a gases flow between the main gases flow path and the humidification source, and results in humidifying the gases in the main gases flow path.

The invention relates to a blood line (108) comprising an infusion site (145) intended to inject into the line a solution, comprising: a first main channel (200) having a first passage section, a second main channel (220) having a second passage section, means for the formation (210) of a turbulence area located downstream from the first main channel, located upstream from the second main channel, these formation means comprising a first fluid passage means (224) defining a reduction (225) in the passage section and whose smallest passage section is smaller than the first passage section and smaller than the second fluid passage section, a secondary channel (230) comprising an inlet (231) for letting in the solution and an outlet (232) in fluid communication with the first main channel or the means for the formation of a turbulence area or the second main channel.